Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Behrad Derakhshan, Chief Business Officer of Edgewise Therapeutics, Inc. (NASDAQ:EWTX), sold 2,491 shares of common stock on August 12, 2025, at prices ranging from $13.36 to $13.49, for a total value of $33,360. The transaction comes as the stock shows recent momentum with a 7.5% gain over the past week, though it remains down 45% over the past six months, according to InvestingPro data.
According to a Form 4 filing with the Securities and Exchange Commission, the transaction resulted in Derakhshan holding 23,645 shares of Edgewise Therapeutics following the sale. The sale was to cover statutory tax withholding obligations related to the vesting of Restricted Stock Units (RSUs) and was not a discretionary sale. The company, currently valued at $1.47 billion, maintains strong liquidity with a current ratio of 28.87 and more cash than debt on its balance sheet.
On the same day, Derakhshan also exercised options to acquire 5,781 shares of Edgewise Therapeutics common stock at a price of $0.00. In addition, Derakhshan acquired 30,000 Restricted Stock Units and options to purchase 180,000 shares of common stock. Analysts maintain a positive outlook on EWTX, with price targets ranging from $14 to $51 per share.
In other recent news, Edgewise Therapeutics reported a narrower-than-expected loss for the second quarter of 2025. The company posted a quarterly loss of $0.34 per share, which was better than analysts’ projections of a $0.42 per share loss. Edgewise Therapeutics also ended the quarter with a solid cash position of approximately $594 million, supporting its ongoing clinical programs. Following these results, RBC Capital raised its price target for the company to $49, maintaining an Outperform rating. Raymond James reiterated its Strong Buy rating with a $46 price target, emphasizing that key catalysts for the company remain on schedule. Notably, the upcoming EDG-7500 Phase 2 CIRRUS-HCM Part D results are expected in the fourth quarter of 2025. Earlier trial data indicated promising efficacy, though there were concerns about a potential atrial fibrillation signal in 14% of patients. These developments reflect the company’s progress and ongoing clinical efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.